Clinical Trials Logo

Actinic Keratoses clinical trials

View clinical trials related to Actinic Keratoses.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06274320 Not yet recruiting - Actinic Keratoses Clinical Trials

Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment

Start date: April 2024
Phase: N/A
Study type: Interventional

This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.

NCT ID: NCT06026358 Not yet recruiting - Actinic Keratoses Clinical Trials

Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

Start date: October 2023
Phase: Phase 4
Study type: Interventional

Interventional, monocentric, national, internal placebo-controlled, prospective pilot study, consisting of two parts, A (single-blinded) and B (open) to assess Efficacy of Tirbanibulin for the treatment of AK on the back of the hand. In part A, eligible subjects receive Tirbanibulin on the left hand and placebo on the right hand for 5 d in a single-blinded manner. Safety and efficacy are assessed at day 8 (± 1 d) (3 days after the end of treatment (EoT+3) and day 57 (± 7 d) after the start of the treatment. Pictures will be taken at baseline, 8 d and 57 d (± 7 d) as per protocol and optional during unscheduled visits.

NCT ID: NCT05923060 Not yet recruiting - Actinic Keratoses Clinical Trials

Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to test a new video device for actinic keratoses. The device takes images of your skin lesions during the treatment, to learn whether this device can predict how well the treatment is working.

NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04429308 Not yet recruiting - Actinic Keratoses Clinical Trials

PDT vs Peels for Treatment of Actinic Keratoses

Start date: January 2025
Phase: Phase 2
Study type: Interventional

The purpose of this study is to to compare photodynamic therapy (PDT) versus the combination of Jessner's solution and 35% trichloroacetic acid (TCA) chemical peels for the treatment of actinic keratoses on upper extremities. This is a randomized clinical trial. Approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives Jessner's solution followed immediately by 35% TCA. AKs will be counted before treatment and 2-8 weeks after treatment. This study is a pilot study designed to determine the feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

NCT ID: NCT04329221 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 1, 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.